


Ask a doctor about a prescription for REVOLADE 25 mg FILM-COATED TABLETS
Package Leaflet: Information for the Patient
Revolade 12.5mg film-coated tablets
Revolade 25mg film-coated tablets
Revolade 50mg film-coated tablets
Revolade 75mg film-coated tablets
eltrombopag
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Revolade contains eltrombopag, which belongs to a group of medicines called thrombopoietin receptor agonists, used to help increase the number of platelets in the blood. Platelets are cells in the blood that help to reduce or prevent bleeding.
ITP is caused by a low platelet count (thrombocytopenia). People with ITP have a higher risk of bleeding. Symptoms that patients with ITP may notice are petechiae (small, round, flat red spots under the skin), bruising, nosebleeds, bleeding gums, and inability to stop bleeding if cut or injured.
Revolade may also be used in patients with low blood cell counts caused by severe aplastic anemia (SAA). SAA is a disease in which the bone marrow is damaged, causing a deficiency of red blood cells (anemia), white blood cells (leukopenia), and platelets (thrombocytopenia).
Do not take Revolade
Consult your doctorif you think this may affect you.
Warnings and precautions
Consult your doctor before starting to take Revolade:
The risk of having a blood clot may be higherin the following circumstances:
If you are in any of these situations, tell your doctorbefore starting treatment. You should not take Revolade unless your doctor considers that the expected benefit outweighs the risk of having blood clots.
Tell your doctorif you are in any of these situations.
Eye examinations
Your doctor will recommend that you have an eye examination to check for cataracts. If you do not have regular eye examinations, your doctor will ask you to have one. They will also examine your retina (the light-sensitive layer at the back of the eye) to see if there is any bleeding in the retina or around it.
You will need to have regular blood tests
Before you start taking Revolade, your doctor will perform a blood test to check your blood cells, including platelets. These tests will be repeated frequently while you are taking the medicine.
Blood tests to check liver function
Revolade may cause changes in your liver function tests, including increased levels of certain liver enzymes, especially bilirubin and alanine/aspartate transaminase. If you are taking interferon, the basic treatment along with Revolade to treat low platelet counts due to hepatitis C, some liver problems may worsen.
You will have blood tests before starting to take Revolade and frequently while taking it to check your liver function. You may need to stop taking Revolade if the levels of these markers increase too much or if you have any other signs of liver damage.
Read the information on “Liver problems” in section 4 of this leaflet
Blood tests to check platelet count
If you stop taking Revolade, it is likely that your platelet count will decrease again within a few days. Your platelet count will be monitored, and your doctor will advise you on what precautions to take.
Very high platelet counts may increase the risk of blood clots. However, blood clots can also form with normal or even low platelet counts. Your doctor will adjust the dose of Revolade to ensure that your platelet count does not become too high.
Seek medical help immediatelyif you have any of these signs of a blood clot:
Tests to examine your bone marrow
In people with bone marrow problems, medicines like Revolade may worsen the problems. Signs of changes in the bone marrow may appear as abnormal results in your blood tests. Your doctor may also perform tests to directly check your bone marrow during treatment with Revolade.
Review of gastrointestinal bleeding
If you are taking interferon, the basic treatment along with Revolade, you will be monitored for any signs of bleeding in your stomach or intestine after you stop taking Revolade.
Heart monitoring
Your doctor may consider monitoring your heart while you are taking Revolade with an electrocardiogram, if necessary.
Elderly (65 years and over)
There is limited data on the use of Revolade in patients aged 65 years or over. If you are 65 or over, you should be cautious when using Revolade.
Children and adolescents
Revolade is not recommended for use in children under 1 year of age with ITP. It is also not recommended for use in children under 18 years of age with low platelet counts due to hepatitis C or severe aplastic anemia.
Other medicines and Revolade
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. This includes medicines obtained without a prescription and vitamins.
Some common medicines may interact with Revolade(including prescription medicines, over-the-counter medicines, and minerals). These include:
Consult your doctorif you are taking any of these medicines. Some should not be taken with Revolade; the dose may need to be adjusted, or you may need to change the times when you take them. Your doctor will review the medicines you are taking and recommend alternatives if necessary.
If you are also taking medicines to prevent blood clots, there is a higher risk of bleeding. Your doctor will discuss this with you.
If you are taking corticosteroids, danazol,and/or azathioprinewith Revolade, you may need to reduce the dose or stop treatment with these medicines.
Taking Revolade with food and drinks
Do not take Revolade with dairy products or drinks, as the calcium in these products affects the absorption of the medicine. For more information, see section 3, “When to take it”.
Pregnancy and breastfeeding
Do not take Revolade if you are pregnantunless your doctor specifically recommends it. The effect of Revolade during pregnancy is not known.
Do not breastfeed while taking Revolade. It is not known if Revolade passes into breast milk.
If you are breastfeedingor plan to breastfeed, tell your doctor.
Driving and using machines
Revolade may cause dizzinessand have other side effects that may make you less alert.
Do not drive or use machinesunless you are sure that Revolade does not affect you.
Revolade contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially “sodium-free”.
Follow the instructions for taking this medicine exactly as your doctor has told you. If you are unsure, consult your doctor or pharmacist again. Do not change the dose or treatment schedule with Revolade unless your doctor or pharmacist advises you to do so. While taking Revolade, you will be under the supervision of a specialist doctor with experience in treating your disease.
How much to take
For ITP
Adults and children(6 to 17 years) - the usual starting dose for ITP is one 50mgRevolade tablet per day. If you are of East or Southeast Asian descent, you may need to start treatment with a lower dose of 25mg.
Children(1 to 5 years) - the usual starting dose for ITP is one 25mgRevolade tablet per day.
For Hepatitis C
Adults- the usual starting dose for hepatitis C is one 25mgRevolade tablet per day. If you are of East or Southeast Asian descent, start treatment with the same dose of 25mg.
For SAA
Adults– the usual starting dose for SAA is one 50mgRevolade tablet per day. If you are of East or Southeast Asian descent, you may need to start treatment with a lower dose of 25mg.
Revolade may take 1 to 2 weeks to work. Depending on your response to Revolade, your doctor may recommend changing your daily dose.
How to take the tablets
Swallow the tablet whole, with water
When to take it
Make sure that –
do notconsume any of the following:
If you do, your body may not absorb the medicine properly.




For more information on what foods and drinks are suitable, consult your doctor.
If you take more Revolade than you should
Consult your doctor or pharmacist immediately. If possible, show them the pack or this leaflet. You will be monitored for signs or symptoms of side effects and given the necessary treatment immediately.
If you forget to take Revolade
Take the next dose at the usual time. Do not take more than one dose of Revolade per day.
If you stop taking Revolade
Do not stop taking Revolade without consulting your doctor first. If your doctor advises you to stop treatment, your platelet count will be monitored every week for four weeks. See also “Bleeding or bruising after stopping treatment” in section 4.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Symptoms to which you need to pay attention: consult your doctor
People taking Revolade for both ITP and low platelet counts associated with hepatitis C may exhibit signs related to potential serious adverse effects. It is essential that you inform your doctor if you develop symptoms.
Increased Risk of Thrombosis
Some people may have a higher risk of having a thrombus, and medications like Revolade can worsen this problem. The sudden blockage of a blood vessel by a thrombus is a rare adverse effect that can affect up to 1 in 100 people.
Seek medical help immediately if you experience signs or symptoms of thrombosis, such as:
Liver Problems
Revolade can cause changes that appear in blood tests, which can be signs of liver damage. Liver problems (increased liver enzymes in blood tests) are frequent and can affect up to 1 in 10 people. Other liver problems are rare and can affect up to 1 in 100 people.
If you have any signs of liver problems:
contact your doctor immediately
Bleeding or Hematoma after Treatment Interruption
Two weeks after interrupting treatment with Revolade, your platelet levels will normally drop to levels similar to those before starting Revolade. A decrease in platelet levels can increase the risk of bleeding or hematoma. Your doctor will check your platelet levels for at least 4 weeks after interrupting treatment with Revolade.
Contact your doctorif you experience bleeding or hematoma when stopping Revolade.
Some people have bleeding in thedigestive systemafter stopping peginterferon, ribavirin, and Revolade. Symptoms include:
Contact your doctor immediatelyif you experience any of these symptoms.
The following adverse effects have been reported in relation to treatment with Revolade in adult patients with ITP
Very Common Adverse Effects
Can affect more than 1 in 10people
Very Common Adverse Effects that can appear in Blood Tests:
Common Adverse Effects
Can affect up to 1 in 10people
Common Adverse Effects that can appear in Blood Tests:
Uncommon Adverse Effects
Can affect up to 1 in 100people:
Uncommon Adverse Effects that can appear in Blood Tests:
The following adverse effects have been reported in relation to treatment with Revolade in children (from 1 to 17 years) with ITP
If these adverse effects worsen, please inform your doctor, pharmacist, or nurse.
Very Common Adverse Effects
Can affect more than 1 in 10children
Common Adverse Effects
Can affect up to 1 in 10children
The following adverse effects have been reported in relation to treatment with Revolade in combination with peginterferon and ribavirin in patients with HCV
Very Common Adverse Effects
Can affect more than 1 in 10people:
Very Common Adverse Effects that can appear in Blood Tests:
Common Adverse Effects
Can affect up to 1 in 10people:
Common Adverse Effects that can appear in Blood Tests:
Uncommon Adverse Effects
Can affect up to 1 in 100people:
The following adverse effects have been observed in relation to treatment with Revolade in patients with severe aplastic anemia (SAA)
If these adverse effects worsen, please inform your doctor, pharmacist, or nurse.
Very Common Adverse Effects
Can affect more than 1 in 10people:
Very Common Adverse Effects that can appear in a Blood Test
Common Adverse Effects
Can affect up to 1 in 10people:
Common Adverse Effects that can appear in a Blood Test
Adverse Effects of Unknown Frequency
Cannot be estimated from the available data
Keep this medication out of sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging and on the blister pack.
This medication does not require special storage conditions.
Medicines should not be thrown away in drains or in the trash. Ask your pharmacist how to dispose of packaging and medicines that are no longer needed. This will help protect the environment.
Composition of Revolade
The active ingredient of Revolade is eltrombopag.
12.5 mg film-coated tablets
Each film-coated tablet contains eltrombopag olamine equivalent to 12.5 mg of eltrombopag.
25 mg film-coated tablets
Each film-coated tablet contains eltrombopag olamine equivalent to 25 mg of eltrombopag.
50 mg film-coated tablets
Each film-coated tablet contains eltrombopag olamine equivalent to 50 mg of eltrombopag.
75 mg film-coated tablets
Each film-coated tablet contains eltrombopag olamine equivalent to 75 mg of eltrombopag.
The other components are: hypromellose, macrogol 400, magnesium stearate, mannitol (E421), microcrystalline cellulose, povidone, sodium carboxymethyl starch, titanium dioxide (E171).
Revolade 12.5 mg and 25 mg film-coated tablets also contain polysorbate 80 (E433).
Revolade 50 mg film-coated tablets also contain: red iron oxide (E172), yellow iron oxide (E172).
Revolade 75 mg film-coated tablets also contain: red iron oxide (E172), black iron oxide (E172).
Appearance and packaging of the product
Revolade 12.5 mg film-coated tablets are white, round, biconvex, engraved with 'GS MZ1' and '12.5' on one side.
Revolade 25 mg film-coated tablets are white, round, biconvex, engraved with 'GS NX3' and '25' on one side.
Revolade 50 mg film-coated tablets are brown, round, biconvex, engraved with 'GS UFU' and '50' on one side.
Revolade 75 mg film-coated tablets are pink, round, biconvex, engraved with 'GS FFS' and '75' on one side.
They are supplied in aluminum blisters in a box containing 14 or 28 film-coated tablets and multiple packages containing 84 film-coated tablets (3 packages of 28).
Only some pack sizes may be marketed.
Marketing authorization holder
Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland
Manufacturer
Lek d.d
Verovskova Ulica 57
Ljubljana 1526
Slovenia
Novartis Pharmaceutical Manufacturing LLC
Verovskova Ulica 57
Ljubljana 1000
Slovenia
Novartis Farmacéutica SA
Gran Via de les Corts Catalanes, 764
08013 Barcelona
Spain
Novartis Pharma GmbH
Roonstraße 25
D-90429 Nuremberg
Germany
Glaxo Wellcome S.A.
Avenida de Extremadura 3
09400 Aranda de Duero
Burgos
Spain
Novartis Pharma GmbH
Sophie-Germain-Strasse 10
90443 Nürnberg
Germany
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
België/Belgique/Belgien Novartis Pharma N.V. Tel: +32 2 246 16 11 | Lietuva SIA Novartis Baltics Lietuvos filialas Tel: +370 5 269 16 50 |
| Luxembourg/Luxemburg Novartis Pharma N.V. Tel: +32 2 246 16 11 |
Ceská republika Novartis s.r.o. Tel: +420 225 775 111 | Magyarország Novartis Hungária Kft. Tel: +36 1 457 65 00 |
Danmark Novartis Healthcare A/S Tlf: +45 39 16 84 00 | Malta Novartis Pharma Services Inc. Tel: +356 2122 2872 |
Deutschland Novartis Pharma GmbH Tel: +49 911 273 0 | Nederland Novartis Pharma B.V. Tel: +31 88 04 52 555 |
Eesti SIA Novartis Baltics Eesti filiaal Tel: +372 66 30 810 | Norge Novartis Norge AS Tlf: +47 23 05 20 00 |
Ελλάδα Novartis (Hellas) A.E.B.E. Τηλ: +30 210 281 17 12 | Österreich Novartis Pharma GmbH Tel: +43 1 86 6570 |
España Novartis Farmacéutica, S.A. Tel: +34 93 306 42 00 | Polska Novartis Poland Sp. z o.o. Tel: +48 22 375 4888 |
France Novartis Pharma S.A.S. Tél: +33 1 55 47 66 00 | Portugal Novartis Farma - Produtos Farmacêuticos, S.A. Tel: +351 21 000 8600 |
Hrvatska Novartis Hrvatska d.o.o. Tel: +385 1 6274 220 | România Novartis Pharma Services Romania SRL Tel: +40 21 31299 01 |
Ireland Novartis Ireland Limited Tel: +353 1 260 12 55 | Slovenija Novartis Pharma Services Inc. Tel: +386 1 300 75 50 |
Ísland Vistor hf. Sími: +354 535 7000 | Slovenská republika Novartis Slovakia s.r.o. Tel: +421 2 5542 5439 |
Italia Novartis Farma S.p.A. Tel: +39 02 96 54 1 | Suomi/Finland Novartis Finland Oy Puh/Tel: +358 (0)10 6133 200 |
Κύπρος Novartis Pharma Services Inc. Τηλ: +357 22 690 690 | Sverige Novartis Sverige AB Tel: +46 8 732 32 00 |
Latvija SIA Novartis Baltics Tel: +371 67 887 070 |
Date of last revision of this prospectus:
Detailed information on this medication is available on the European Medicines Agency website http://www.ema.europa.eu.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for REVOLADE 25 mg FILM-COATED TABLETS – subject to medical assessment and local rules.